IP Library Granted Patent US 8,828,953
Granted Patent B2
US 8,828,953 · App. 12/907,909 · Granted Sep 9, 2014

Chemosensory receptor ligand-based therapies

Inventors: Alain Baron (San Diego, CA); Martin R. Brown (Coronado, CA); Christopher R. G. Jones (San Diego, CA)
Assignee: NaZura BioHealth, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,828,953
App. No.
12/907,909
Granted
Sep 9, 2014
Kind
B2
Abstract

Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.

Claims (22)

1. A composition comprising a sweet receptor ligand, wherein the sweet receptor ligand is a non-nutritive agonist of the receptor and the composition is adapted to release the sweet receptor ligand to one or more of the duodenum, jejunum, ileum, caecum, colon and/or rectum of a subject.

2. A composition according to claim 1 , wherein the composition further releases at least some of the sweet receptor ligand in the stomach.

3. A composition according to claim 1 , wherein the composition is adapted to release the sweet receptor ligand distal to the duodenum.

4. A composition according to claim 3 , wherein the composition is adapted to release the sweet receptor ligand to the jejunum, ileum, caecum, colon and/or rectum.

5. A composition according to claim 1 , wherein the composition releases at an onset of about 5 to about 45 minutes, about 105 to about 135 minutes, about 165 to about 195 minutes, about 225 to about 255 minutes or a combination of times thereof following administration to a subject.

6. A composition according to claim 1 , wherein the composition releases at an onset of about pH 5.0, about pH 5.5, about pH 6.0, about pH 6.5, about pH 7.0, or a combination thereof following administration to a subject.

7. A composition according to claim 1 , wherein the composition further comprises a bitter receptor ligand, an umami receptor ligand, a fat receptor ligand, a bile acid receptor ligand or any combination thereof.

8. A composition according to claim 1 , wherein the non-nutritive sweet receptor ligand is selected from the group consisting of sucralose, aspartame, Stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C , Rebaudioside D, Rebaudioside E, Rebaudioside F, Neotame, acesulfame-K and saccharin.

9. A composition according to claim 7 , wherein the bitter receptor ligand is selected from the group consisting of a flavanone, a flavone, a flavonol, a flavan, a phenolic flavonoid, an isoflavone, a limonoid aglycone, a glucosinolate or hydrolysis product thereof and an organic isothiocyanate.

10. A composition according to claim 7 , wherein the umami receptor ligand is selected from the group consisting of glutamate salt, glutamine, acetyl glycine and aspartame.

11. A composition according to claim 7 , wherein the fat receptor ligand is selected from the group consisting of a linoleic acid, an oleic acid, an omega-3 fatty acid, a palmitate, an oleoylethanolamide, a mixed fatty acid emulsion and an N-acylphosphatidylethanolamine (NAPE).

12. A composition according to claim 7 , wherein the bile acid receptor ligand is selected from the group consisting of deoxycholic acid, a taurocholic acid and a chenodeoxycholic acid.

13. A composition according to any one of claims 1 - 12 , further comprising an enhancer.

14. A composition comprising a non-nutritive agonist to a sweet chemosensory receptor wherein the composition has a sweetness potency of at least about 100 times the sweetness potency of sucrose, and wherein the composition is adapted to release the agonist to one or more of the duodenum, jejunum, ileum, caecum, colon and/or rectum of a subject.

15. A composition according to claim 6 , wherein the composition releases at more than one pH range.

16. A composition according to claim 14 , wherein the composition has a sweetness potency of at least 500 times the sweetness potency of sucrose.

17. A composition according to claim 14 , wherein the composition has a sweetness potency of at least 1000 times the sweetness potency of sucrose.

18. A composition according to claim 14 further comprising a bitter receptor ligand, an umami receptor ligand, a fat receptor ligand, a bile acid receptor ligand, or any combination thereof.

19. A composition comprising a non-nutritive agonist to a sweet chemosensory receptor wherein the composition has a sweetness potency equivalent to at least about 500 grams of sucrose, and wherein the composition is adapted to release the agonist to one or more of the duodenum, jejunum, ileum, caecum, colon and/or rectum of a subject.

20. A composition according to claim 19 , wherein the composition has a sweetness potency equivalent to at least about 5000 grams of sucrose.

21. A composition according to claim 19 , wherein the composition has a sweetness potency equivalent to at least about 10000 grams of sucrose.

22. A composition according to claim 19 further comprising a bitter receptor ligand, an umami receptor ligand, a fat receptor ligand, a bile acid receptor ligand or any combination thereof.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2016
From: NAZURA BIOHEALTH, INC.
To: ELCELYX THERAPEUTICS, INC.
Reel/Frame 038727/0580 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2016
From: ELCELYX THERAPEUTICS, INC.
To: AMBRA BIOHEALTH LLC
Reel/Frame 038727/0924 →
CHANGE OF NAME Recorded May 26, 2016
From: AMBRA BIOHEALTH LLC
To: AMBRA BIOSCIENCE LLC
Reel/Frame 038823/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2014
From: ELCELYX THERAPEUTICS, INC.
To: NAZURA BIOHEALTH, INC.
Reel/Frame 033393/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2010
From: BARON, ALAIN; BROWN, MARTIN R.; JONES, CHRISTOPHER R.G.
To: ELCELYX THERAPEUTICS, INC.
Reel/Frame 025400/0607 →
Continuity (3)
Continuation In Part 12763926 · Apr 20, 2010
Provisional Application 61170657 · Apr 20, 2009
Related Publication 20110065660A1 · Mar 17, 2011